Attention Administrator - database is in test mode!
Ablexis is a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for the efficient discovery and development of the next wave of human therapeutic antibodies. Ablexis is commercializing the AlivaMab Mouse platform through partnering strategies that provide broad, non-exclusive access with no target or field-of-use restrictions.
Adynxx is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Afraxis is discovering and developing drugs to treat rare and neglected diseases through the modulation of p21-activated kinase (PAK). Afraxis' initial indication of interest is Fragile X syndrome with expansion into other diseases of the central nervous system, including schizophrenia and autism spectrum disorders. PAK is also implicated in cancer, including Neurofibromatosis, a rare form of cancer for which there are no approved drugs. Inhibiting PAK activity has the potential to induce significant anti-tumor activity.
Alcresta is developing and commercializing innovative enzyme-based nutritional products that improve patient health and manage disease for infants, older adults and patients battling acute or chronic conditions. Leveraging its existing proprietary platform of nutritional products and medical devices, Alcresta has developed a lead program designed to improve the delivery, digestion and absorption of long-chain polyunsaturated fatty acids (including omega-3 and omega-6) to support pediatric growth and development, help strengthen the immune system, accelerate the recovery of patients battling acute or chronic conditions, and enhance active adult nutrition.
AliveCor aims to provide medical professionals, patients (be they human or animal), and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and treat life-altering diseases from anywhere in the world. As a first offering, AliveCor has developed a clinical-quality, low-cost ECG recorder that enables patients to monitor their heart health anywhere, at any time and provides physicians with a more comprehensive assessment. The AliveCor smartphone ECG is designed to work in conjunction with a variety of mobile platforms, including iPhone, iPad, and Android devices.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. The company was founded in 2011 by industry leaders with a proven track record of success in protein therapeutic design and development. Allena is leveraging its leadership team's combined operational expertise in manufacturing, formulation and non-systemic protein delivery.
AMSilk is the first company to manufacture spider silk, a high performance protein that can be used for medical devices, wound healing, pharmaceutical products and fibers. The company's unique biotechnological process, invented at the Technische Universität München, has been scaled to industrial size for ton-scale production. AMSilk's spider silk retains the performance properties of natural spider silk, is biocompatible and can be processed into films, coatings, foams, nonwovens and fibers. AMSilk is developing several wound treatments and technical fibers (Biosteel® ) for medical and ballistic textiles.
Apexigen is a biotherapeutic development company advancing antibody drug candidates for the treatment of cancer and other serious diseases. The pipeline is led by APX005, an antibody that both exerts direct anti-tumor actions and activates an anti-tumor immune response. Four other product candidates are currently under development through collaborations. The company’s proprietary rabbit-derived humanized antibody technology platform enables the discovery of a broad diversity of antibodies to a target antigen. This great diversity of antibodies enables the discovery of antibodies with rare or specific biological properties, which may become the next generation of breakthrough therapeutics. Apexigen is employing its strategy to develop innovative bio-therapeutics, advance its product pipeline, and see that important new therapies are made available to patients.
Based on its aptamer technology platforms, Aptamer Sciences Inc. is a privately held biotech company focused on commercializing technologies for analysis of proteins. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics.
Aratana Therapeutics licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and develops strategies to maximize the value of the programs. The company is developing novel compounds to address unmet and under-served medical needs in in companion animal care including pain, cachexia, and frailty. These compounds are supported by substantial safety and effectiveness data and will represent best- or first-in-class products in the animal health industry.
Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis. Array Bridge has developed "antibody arrays" to measure biosimilar drug comparability at the molecular level, providing a measurement of biosimilar conformational comparability. This antibody array-based technology can be used at all stages of biosimilar development, from cell line selection and process development to clinical testing and product release. For impurity analysis, the company provides ELISA kits and reagents for Host Cell Protein quantitation and Western Blot analysis.
Asthmapolis is dedicated to improving the management of asthma for patients and healthcare professionals. It uses medication sensors, mobile applications, advanced analytics and feedback to help physicians identify those patients who need more help controlling the disease.
Avia Biosystems' products provide solutions to common bottlenecks that limit the development and formulation of biologics. The first product developed by the company, the fluorescence-based Model 2304 Fully Automated Protein Denaturation System, automates protein stability studies, with primary applications in stability testing of protein constructs during discovery and development and biologics formulation stability testing during pre-clinical and clinical development. The system automatically prepares samples and the requested array of buffer and excipient conditions, collects fluorescence data, and processes the data for up to 96 protein samples or formulations.
Base Pair Biotechnologies is a spin-off of parent company BioTex, a developer of several molecular biology and diagnostic technologies. Scientists at Base Pair Bio have been studying aptamers and developing them on a research basis and offer these services commercially.
Bina is the big data science platform for large scale secondary and tertiary genomic analysis. Bina uses big data and cloud technologies to process raw genetic data in order to help clinicians and researchers administer treatment based on an individual's unique DNA. Bina's mission is to accelerate personalized medicine using whole genome analysis. The company was founded in 2011 by a team of Stanford and Berkeley researchers, data scientists, bioinformaticians, and entrepreneurs.
BioLamina is a rapidly expanding biotechnology company within the stem cell and cell differentitation fields. Started as recently as 2009, it is already acknowledged as one of Sweden’s 33 most promising young technology companies. BioLamina produces and sells high-quality human recombinant laminins that are the foundation on which cells grow in vivo – and most likely the optimal surface for stem cells, primary cells and cell differentiation in vitro.
BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to increase efficacy whilst reducing side effects. MOTI1001 is BioMoti's lead Oncojan™ based ovarian cancer candidate. Oncojans are a new class of therapeutic microparticles that can target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
Blueprint Medicines is committed to improving the lives of cancer patients by transforming genomically-defined subsets of cancer from life-threatening diseases to manageable conditions. Blueprint Medicines is harnessing the potential of the cancer genomics revolution by rapidly translating emerging insights into impactful drug programs.
BlueSEQ helps research labs, universities, hospitals, and genome centers around the world design and outsource next-generation sequencing projects. The company matches sequencing service needs with providers that have the right next-generation sequencing technology and expertise. BlueSEQ provides a neutral source of market and technical information to support optimal next-generation sequencing project design and service provider compatibility.
Cardeas is a privately held pharmaceutical company dedicated to the development and commercialization of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.
Cardio3 BioSciences is a biopharmaceutical company involved in the discovery, development, and commercialization of regenerative and protective therapies for cardiovascular diseases.The aim of these therapies is to protect the heart during myocardial injury, reduce the volume of the scar and reconstruct damaged heart tissue. The company’s product candidates and research programs are based on the proprietary Cardiopoiesis technology platform, which is based on fundamental research conducted at Mayo Clinic.
Catabasis is a clinical stage company that develops products to target inflammatory, immunological and metabolic diseases. It's SMART linker platform technology produces new chemical entities that have amplified efficacy along a clinically validated disease pathway through the conjugation of two known products via a linker that is metabolized intracellularly in cells relevant to the particular disease.
Cellworks has built a pipeline of drug candidates for cancer and rheumatoid arthritis by implementing a novel approach to therapeutic design and development. The Cellworks approach combines a predictive and responsive network of protein interactions with sophisticated algorithms to emulate human physiology and predict clinical outcomes early on. The company is using this technology to design novel mechanism of actions by combining existing FDA approved drugs that work synergistically to impact multiple disease pathways simultaneously.
Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cancers by targeting protein homeostasis through the ubiquitin proteasome and autophagy systems, an area of unrealized potential. Cleave is using molecular profiling approaches with the goal of identifying patient subsets most likely to benefit from each of its targeted drugs.
Curiox Biosystems develops and commercializes cellular assay systems. Its first product, the DropArray™ platform, is intended to accelerate the progress of basic research, drug discovery and diagnostics through the miniaturization and automation of bioassays. The Curiox DropArray platform allows scientists to perform low-volume cellular assays efficiently using adherent, weakly adherent and even non-adherent cells, achieving long-term on-plate incubations without evaporation. Curiox recently introduced the LT210 (low throughput) or HT200 (high throughput) DropArray Washing Stations to automate the task of adding or changing media and buffers.
CytomX is a biotechnology company focused on improving the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's Probody™ Platform represents a transformational drug discovery and development approach for antibodies, enabling improved specificity, increased efficacy and decreased toxicity.
Dezima Pharma develops drugs to treat dyslipidemia, a major modifiable risk for cardiovascular disease. Its objective is to develop compounds from pre-clinical development to meaningful proof of concept in patients. Dezima will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications. The Netherlands-based company was founded by Forbion Capital Partner and BioGeneration Ventures.
Dynamic Biosensors develops and commercializes the proprietary switchSENSE technology for molecular interaction analysis. In addition to binding affinity and kinetics, the dynamic character switchSENSE allows to determine molecular size, conformational changes, charge, and certain post-translational modifications of the target in the same measurement. Dynamic Biosensors is a spin-off of the Technische Universität München.
eADMET is an expert in the creation of customized computational models for the prediction of important ADME/Tox properties of small drug-like molecules. The company’s modular approach combines proprietary and selected external algorithms to inform the creation of customized prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.
Elcelyx Therapeutics is a privately-held company developing products for weight management and obesity-related metabolic disorders based on the science of nutrient sensing. Elcelyx product candidates, Lovidia™ and NewMet™, are Gut Sensory Modulators backed by research and clinical data demonstrating their ability to rapidly reduce weight and improve glucose metabolism without systemic side effects, respectively.
Ember Therapeutics is a product-focused company translating its biology in the emerging area of brown fat and recent breakthroughs in understanding the mechanisms of selective insulin sensitivity into a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes and obesity.
Envoy’s mission is to change drug discovery by advancing new drugs that act on targets expressed specifically in the cell populations important to diseases. Their goal is to bring forth drugs that help millions of people while causing fewer side effects. Envoy hopes to achieve this mission through their powerful technology, called “bacTRAP”, that allows them to measure, in vivo, the expression of each protein within any given cell type.
Eqalix is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing nano-materials for the repair and regeneration of diseased, traumatized, and aging tissues. The company plans to develop and commercialize a plant-protein based nano-fiber scaffold for use in consumer markets and as a human skin substitute; small-diameter hybrid vessels that foster the creation of a functional endothelium after implantations; and 3D tissue scaffolds with adjustable properties for organ and tissue replacement and repair.
Eudendron is a start-up company devoted to the discovery and development of a new generation of Kinase inhibitors in the area of oncology personalized medicine. The company's molecular design aims to develop safer and effective drugs able to overcome drug resistance. Eudendron’s new generation of Kinase inhibitors will be the result of a drug process called KemKinase, which encloses molecular designs and in silico validation technology coupled to a Kinome-wide strategy, revealing at a very early stage the full spectrum of Kinase targets associated to the newly identified chemical classes.
Flexion Therapeutics discovers and develops innovative therapeutics for musculoskeletal disorders. In order to provide safe and effective products, they are merging novel pharmacology with local, sustained delivery of drug to the site of disease; an approach that aims to ensure lasting therapeutic effect and systemic safety.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s initial clinical product, FoundationOne™, is a fully informative genomic profile to identify a patient’s individual molecular alterations and match them with relevant targeted therapies and clinical trials.
Gamma Therapeutics is an early stage biotechnology venture developing solutions for cardiovascular disease risk assessment, biosurgical therapy and combat casualty care based upon the use of human biocompatible proteins, such as Gamma Prime Fibrinogen, responsible for the clotting mechanism in human blood. The product line includes its patent-pending flagship product, GammaCoeur™, a cardiovascular disease risk assessment assay; GammaSeal™, a patented, high strength surgical incision and wound healing sealant; Gammarin™, a patented anticoagulant blood thinner for use during and after surgery, and; GammaTF, a provisionally-patented fast-clotting hemostatic dressing for hemorrhage control.
Genea Stem Cells (GSC) develops disease-specific pluripotent and differentiated human cells for use in drug discovery and research. Based on the world’s largest private bank of human embryonic stem cells (about 100 lines/30 diseases), GSC supplies application-ready, disease-affected and control differentiated cell types and works collaboratively with industry for custom-developed cell-based assay solutions in drug development. All of GSC’s cell products are genetically unmodified human cells - the most accurate in vitro reflection of clinical conditions.
GigaGen envisions a future where doctors routinely use an immune "fingerprint" to help manage complex medical problems such as transplantation, autoimmune disease, and cancer. The GigaMune™ technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize your immune system into an immune "fingerprint".
Global Blood Therapeutics is a product-focused company building a pipeline of innovative, oral medicines to improve the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options. The company's unique SHAPE Platform is enabling the discovery and development of small molecule drugs that change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits.
Gradalis is a privately-held, fully-integrated biotechnology company based in Dallas, Texas that is developing, manufacturing and commercializing drugs, vaccines, tools and diagnostics primarily in the area of cancer. The company has two platforms: one focused on personalized autologous vaccines and the other on bifunctional short hairpin RNA delivered via a proprietary lipoplex system. Recently-published data showed that FANG, the company’s autologous tumor vaccine, showed significant survival benefit in patients with advanced disease for multiple types of cancer. Gradalis has its own state of the art GMP manufacturing facility, as well as a strategic partnership with Mary Crowley Cancer Research Centers for early stage clinical development of Gradalis products.
Helmedix, a start-up company from the ithree institute at the University of Technology Sydney, is a biopharmaceutical company developing therapies for autoimmune diseases based on peptides derived from a helminth parasite. Helmedix will be managed as a virtual company, based in Sydney, with research contracted to Dr Donnelly’s team at the ithree institute.
Hepregen's mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients' lives. The company is focused on advancing and commercializing its microliver platform, HepatoPac™, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen's platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery.
HiberGene is developing a molecular diagnostic test for meningitis which can be used to test for the presence of the two most common forms of the disease, Meningococcus and Pneumococca. The test uses a rapid isothermal amplification platform allowing accurate results to be delivered in less than forty minutes. The company intends to develop a range of tests for a number of infectious human diseases including healthcare associated infections and sexually transmitted Infections.
Hookipa Biotech, founded in Vienna, Austria in summer 2011, develops a new class of innovative prophylactic and therapeutic vaccines. The Vaxwave® technology is a vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The company currently focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave® technology and build a robust product pipeline. Hookipa has recently moved into its BSL2 facility at the Campus Vienna Biocenter.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management.
JB Therapeutics, a clinical stage biopharmaceutical company, is developing JBT-101 a nanomolar cannabinoid agonist which activates the CB2 receptor present on immune cells and fibroblasts. Upon binding CB2, JBT-101 stimulates the production of specific lipid mediators (PGJ2, LXA4) which act to turn off inflammation and fibrosis. The product is a pharmaceutical capsule containing a pure synthetic derivative of THC with minimal blood brain barrier penetration. It is currently being developed as a potential disease modifying treatment for the orphan disease scleroderma.
Jounce Therapeutics is a private company launched in 2013 and based in Cambridge, Massachusetts. The company is dedicated to transforming the treatment of cancer by focusing on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or to stop the progression of cancer. Kancera is currently running two pharmaceutical development projects, one relating to solid tumors and one relating to leukemia. Through a subsidiary, Kancera also provides big pharma, mid-sized pharma and biotech companies with lead identification and optimization services such as high-throughput screening (HTS), fragment-based screening (FBS), assay development and medicinal chemistry.
KemPharm is a development stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company’s primary efforts include the development of safer abuse resistant opioid pain relievers. The company’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies for multiple cancer indications. Kite is advancing a portfolio of product candidates designed to leverage and enhance the patient's own immune system to fight tumor cells. These personalized immunotherapies are aimed at providing significant and durable clinical benefit in a wide range of tumor indications.
LabMinds develops, manufactures and sells next generation solutions for laboratory challenges with a particular focus on combining advanced laboratory products with leading edge usability and network technologies. LabMinds' lead product, EasySolution, automates the ubiquitous process of solution preparation worldwide, combining features such as water purification, solid storage, solid dosing, weighing, stirring, temperature control, pH control, vacuum filtering, label printing and GMP/GLP adherence in one extremely usable solution.
Meritage Pharma is committed to the development of prescription products for the treatment of gastrointestinal and atopic diseases. The company is currently developing oral budesonide suspension (OBS) intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract.
MiReven was formed in 2010 through an investment from the Medical Research Commercialization Fund. The company is commercializing the pioneering work of Peter Leedman and Dr. Keith Giles at the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7. According to the company, miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor, as well as its associated signaling pathways that promote cancer development.
Molecular Response is an oncology-focused CRO, with a viable primary tumor bank of more than 140,000 clinical biopsies, spanning 76 diagnoses. Tumors are employed to create Patient-Derived Xenograft (PDX) models, 3D cell culture for ex-vivo pharmacology studies, and genomic surveys for target prevalence. Tumors have histology/pathology reports, ex-vivo drug resistance data and matched FFPE blocks. These platforms allow for in vivo and ex-vivo drug candidate selection, patient stratification, biomarker verification, and development of Companion Diagnostic assays in CAP/CLIA-accredited labs.
Nabsys is working on enabling advances in life sciences and healthcare through strategic deployment of a novel positional sequencing platform with broad applicability for DNA analysis. The Nabsys DNA analysis platform employs fully solid state nanodetectors that reveal both the identity and location of DNA sequences over long distances (10’s to 100’s of thousands of bases). The technology employs electronic detection that permits the location of sequences to be identified in a highly accurate and rapid manner. This approach allows for the identification of sequence variants of all length scales applicable to diagnostics, agriculture and whole genome sequencing.
NanoOncology is a biotechnology company that was recently purchased by PeptiMed. Its mission is to identify specific tumor-causing genetic targets and designing small interfering RNA (siRNA)-based drugs and small molecules drugs that inhibit the tumor promoting function of gene products for each patient on an individual basis. The company invented EVIRNA ™, a proprietary siRNA therapeutic drug that targets the EVI1 gene for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer. NanoOncology also invented a unique polypeptide-based nanoparticle system for delivery of siRNA directly to tumor cells.
NanoTemper Technologies GmbH develops, produces and markets innovative, high quality instruments for bio-medical research. The company, a spin off from the University of Munich (LMU), has developed Microscale Thermophoresis (MST) a new technology for biomolecular interaction measurements. The company was founded in 2008 and it has been expanding globally ever since.
NanoViricides applies nanomedicine technologies to the treatment of viral diseases. The nanoviricide® has a peptide on its surface that the company designs which mimics what's expressed on the surface of the target cell of the virus. The attachment of the surface protein of the virus to the "mimic" causes a conformational change in the nanoviricide® which then encapsulates the virus, destroying it. This has been demonstrated in over 4000 animals with 9 different viral-induced diseases.
Oligomerix is a biopharmaceutical company focused on small molecule drug discovery, immunotherapy approaches, and biomarker assay development for Alzheimer’s disease (AD) and other neurodegenerative disorders. Its platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates.
Persomics has developed technology to mass-produce arrays for high content cell based screening. Their printing technology miniaturizes thousands of high content screening points onto an array, accelerating screening. Persomics mass production technology enables large scale production of high content screening arrays for the first time, providing a cost effective tool for accelerating gene and drug discovery.
PolyActiva is a biotechnology company developing drug-polymer conjugates that allow for site specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. The company has completed proof of concept studies on these and is working towards developing first products. PolyActiva is interested in medical technology companies looking to incorporate PolyActiva’s drug eluting components in their devices. PolyActiva is a joint venture between CSIRO and the Bionic Ear Institute and is located in Melbourne, Australia.
Practichem is a biotechnology company specializing in chromatographic instrumentation and consumables. With a focus on both protein and small molecule purification markets, Practichem’s current product line includes their Protein Purification Instrument, ARISTA and flash consumables. A performance flash chromatography instrument is also in development.
Progenitor Labs is a biotechnology company developing stem cell technologies to discover drugs that regenerate tissues of the human body. Their vision is to develop medicines that instruct organs such as the blood, muscle, bone, heart and brain to regenerate in response to injury, disease or ageing.
Prokarium is a biotechnology company with a vision to create the best platform for oral delivery of almost any recombinant protein vaccine. Its Vaxonella™ platform incorporates genetic and formulation technologies that are designed to optimize live bacterial vector-mediated antigen delivery: Spi-VEC, X-mark, ORT-VAC and BAR. Prokarium is based in Keele and London, UK.
Roslin Cellab is a stem cell technology company, providing stem cell contract research and product development work for academic and commercial clients in the life science, biotechnology, and pharmaceutical sectors. The company provides the opportunity to explore and exploit stem cell biology in regenerative medicine and is currently developing a number of human liver cell products which it hopes to begin making available to the drug discovery sector soon.
SAMDI Tech is a CRO that offers label-free assay services for assay development, high throughput screening, and peptide substrate discovery. The company uses its SAMDI label-free technology to perform rapid and quantitative assays of challenging biochemical targets. SAMDI is an HTS mass spectrometry tool that eliminates the need for cumbersome antibodies, fluorescence, and radioactive labels.
Soluble Therapeutics commercialized the HSC™ Technology, a platform for optimizing protein formulations that can increase the solubility and stability of proteins for use as therapeutics, vaccines, diagnostics, and research reagents. The HSC Technology combines high-throughput self-interaction chromatography with a predictive algorithm to compress the amount of time it takes to derive optimal formulations for the protein in question. The HSC Technology is available on a fee-for-service basis, or companies can purchase the HSC instrument for use in their own laboratories.
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. The company’s lead product, TMX-101, proved to have a good safety profile in humans during the first stage of a Phase I/II clinical trial for the localised treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Tunitas Therapeutics is a privately held biopharmaceutical company that is developing targeted protein therapeutics. Tunitas’ proteins are capable of altering the natural course of such allergic diseases as food allergies, asthma, rhinitis and atopic dermatitis. The company’s therapeutic approach offers the potential for long-lasting treatments. Tunitas is also developing a next-generation immunotherapy platform of fusion proteins which offer the prospect of long-term relief for specific allergic diseases.
Ubiquigent Limited is a specialist developer and supplier of high quality reagents, kits, and drug discovery assay development and compound profiling services to the life science research community worldwide. Ubiquigent's scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.
Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world’s most powerful medicinal chemist, Warp Drive Bio is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within microbes. Key to the Warp Drive Bio approach is the company’s proprietary “genomic search engine” and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signature.
XL-protein is a privately owned German biotech company commercializing the PASylation technology, which allows the extension of the plasma half-life of biopharmaceuticals. XL-protein focuses on the preclinical and clinical development of PASylated proteins in several disease areas. Its goal is to provide improved second-generation biopharmaceuticals allowing less frequent and lower dosing together with better tolerability, making treatment cheaper and supporting patient compliance and safety.
You are now a GEN Select Insider!
You now have access to in-depth reports, peer reviewed papers and hot jobs.